← Human Trials & Peer-Reviewed Studies
Vitamin D supplementation has no effect on matrix metalloproteinases-2, -9, and tissue inhibitor matrix metalloproteinase-1 in subjects with metabolic syndrome: A pilot study.
Plain-language guide to PMID 30829137 (2019): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 30829137
- Journal
- International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- Ghezel A et al. (5 authors)
- DOI
- 10.1024/0300-9831/a000559
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.
The present randomized, double-blind, placebo controlled study aimed to evaluate the effect of vitamin D supplementation on matrix metalloproteinases-2, -9 (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in subjects with metabolic syndrome.
Why It Was Studied
Moreover, dietary intake, sun exposure and physical activity were also determined.
Who Took Part
By PubMed's age tags, the people studied were adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and pilot.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.
Metabolic and anthropometric indices, serum MMP-2, MMP-9, TIMP-1 and high-sensitivity C-reactive protein (hsCRP) were assessed before and after intervention.
What Was Measured
Topics PubMed links to this paper include Dietary Supplements, Matrix Metalloproteinase 2, Matrix Metalloproteinase 9, Metabolic Syndrome, Pilot Projects, Tissue Inhibitor of Metalloproteinase-1 and Vitamin D.
Author keywords: tissue inhibitor of matrix metalloproteinase.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.
The publication is from 2019 (International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition), a journal based in Singapore.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.